Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Refractory Metastatic Colorectal Cancer
NCT03542877Phase 2Completed
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in colorectal cancer (CRC), sponsored by Academic Thoracic Oncology Medical Investigators Consortium. Primary endpoint: 12-Week Progression Free Survival. Started Jun 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03542877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542877.